



Investor Fact Sheet

Financial key figures 2022/23

(Audited Swiss GAAP FER figures)

in thousand CHF


	2022/23	in %	2021/22	in %	Change	in %
Sales of goods and services group	497 460	100.0 %	464 841	100.0 %	32 618	7.0 %
thereof continuing business group	440 480		380 274		60 205	15.8 %
Ypsomed Delivery Systems (YDS)	307 807	61.9 %	259 036	55.7 %	48 771	18.8 %
Ypsomed Diabetes Care (YDC)	173 530	34.9 %	187 490	40.3 %	-13 959	-7.4 %
thereof continuing business YDC	116 550		102 923		13 628	13.2 %
Others	16 122	3.2 %	18 316	3.9 %	-2 194	-12.0 %
Gross profit	140 591	28.3 %	113 817	24.5 %	26 775	23.5 %
Operating profit group	60 594	12.2 %	28 579	6.1 %	32 015	112.0 %
thereof continuing business group	39 372		24 239		15 133	62.4 %
Financial income	3 164	0.6 %	3 045	0.7 %	119	3.9 %
Financial expenses	-7 121	-1.4 %	-6 083	-1.3 %	-1 038	17.1 %
Income taxes	-5 362	-1.1 %	-2 435	-0.5 %	-2 927	120.2 %
Net profit	51 275	10.3 %	23 105	5.0 %	28 170	121.9 %

Earnings per share in CHF	3.82		1.83		1.99	109.0 %
----------------------------------	-------------	--	------	--	------	---------


Operating profit	60 594	12.2 %	28 579	6.1 %	32 015	112.0 %
Depreciation and impairment of fixed assets	41 810		40 273		1 537	3.8 %
Amortisation and impairment of intangible assets	36 750		27 808		8 942	32.2 %
EBITDA (Operating profit before depreciation and amortisation)	139 154	28.0 %	96 660	20.8 %	42 494	44.0 %

Equity ratio in %	65.2 %		51.9 %		13.4 %	
Investments in fixed assets	98 717		50 537		48 180	95.3
Investments in intangible assets	79 700		57 977		21 723	37.5
Number of employees	2 059		1 923		136	7.1
Number of full-time positions	1 978		1 831		147	8.1

Sales at group level



EBIT at group level



¹ DiaExpert GmbH sold as per 31 December 2022

Further information on significant shareholders and shareholder groups as well as other financial figures of the Ypsomed Group can be found in the Annual Report 2022/23 and at www.ypsomed.ch.



Ypsomed Diabetes Care

With its mylife Diabetescare brand, Ypsomed operates successfully in the B2C business with products and services for people with diabetes mellitus. The product portfolio includes: insulin pumps, infusion sets, pen needles, blood glucose monitoring systems and other diabetes supplies. Products are distributed via Ypsomed's subsidiaries to hospitals, doctors, pharmacies and patients, and via distributors (pen needles).

Diabetes: A global disease with pandemic growth predicted in the coming 20 years. Currently diabetes is growing at approximately 9 % p. a.

mylife product portfolio (selection)



Ypsomed Delivery Systems

Our pharmaceutical and biotech customers purchase injection systems and corresponding services under the YDS brand, Ypsomed Delivery Systems. They do this via the industry leader, as Ypsomed is the world's largest developer and manufacturer of pens and autoinjectors with which people can administer their liquid medication subcutaneously themselves.

Trends for future drugs: Drugs are becoming more specific, e.g. in the treatment of autoimmune diseases. Next to generic drugs, a large number of new, very specific drugs come onto the market. New drugs for Alzheimer's disease, obesity and rare diseases are being developed. Cancer drugs are also becoming more specific. Efforts to develop active ingredients for subcutaneous injection open up opportunities for self-medication with auto- and patch injectors.

YDS product portfolio (selection)



Legal disclaimer: The information contained in this document has not been independently verified and no representation or warranty, expressed or implied, is made to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained herein. Neither Ypsomed Holding AG, its advisors or representatives, nor their respective affiliates shall have any liability whatsoever for any loss whatsoever arising from any use of this document, or its content, or otherwise arising in connection with this document. This document does not constitute, or form part of, an offer to sell or a solicitation of an offer to purchase any shares and neither it nor any part of it shall form the basis of, or be relied upon in connection with, any contract or commitment whatsoever. This document contains forward-looking statements which involve risks and uncertainties. These statements may be identified by such words as "may", "plans", "expects", "believes" and similar expressions, or by their context. These statements are made on the basis of current knowledge and assumptions. Various factors could cause actual future results, performance or events to differ materially from those described in these statements. No obligation is assumed to update any forward-looking statements.